TO THE EDITOR
H2AX is a core histone known to be involved in the cellular response to DNA double-strand breaks (DSBs); following DSBs, H2AX is rapidly phosphorylated (g-H2AX) 1 and is thought to play a role in recruiting DNA repair factors to the site of damage. 2 In H2AX À/À mice, V(D)J recombination does not seem to be affected, although the numbers of T-and B-lymphocytes are reduced by 50%. However, class switch recombination appears to be impaired as evidenced by reduced switching to IgG. 3 Recently, H2AX was proposed to be important in maintaining genomic stability, particularly in the context of p53 deficiency. 4, 5 Loss of a single H2AX allele compromises genomic integrity, via increased chromosomal aberrations, while on a p53-deficient background it enhances cancer susceptibility, promoting, among others, B-lineage lymphomas that tend to have mature features. 4, 5 Furthermore, H2AX
À/À p53 À/À mice have an increased number of translocations and develop various tumors including immature T-and B-cell lymphomas. 4, 5 The H2AX gene maps to chromosome 11q23, a region which is frequently altered in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia. 6 Since there are indications that H2AX deficiency could promote B-cell tumorigenesis, we screened DNA from 112 tumors from seven different B-cell leukemia/lymphoma entities for mutations in the H2AX gene. The subtypes analyzed were diffuse large B-cell lymphoma (n ¼ 13), follicular lymphoma (n ¼ 15), chronic lymphocytic leukemia (n ¼ 17), childhood pre-B acute lymphoblastic leukemia (n ¼ 20), MCL (n ¼ 11), hairy cell leukemia (n ¼ 20) and lymphoplasmacytic lymphoma/Waldenströ m's macroglobulinemia (n ¼ 16). Primers were designed to PCR amplify the coding region of the gene (H2AFX, Genbank NM_002105), giving a product of 581 bp, which encompassed the 432 bases of coding sequence. Primer sequences were: forward primer, 5 0 -3 0 CGGGCGTCTGTTCTAGTGTT; and reverse primer, 5 0 -3 0 GGCTCAGCTCTTTCCATGAG. All PCR products were sequenced using the same primers as used in the PCR reaction. No mutations were found in any of the B-cell leukemias or lymphomas investigated.
Although recently suggested to be a putative dosagedependent tumor suppressor or caretaker gene involved in tumorigenesis, 4, 5 H2AX is not inactivated in B-cell leukemias/ lymphomas by point mutations. However, since many B-cell lymphomas have deletions of chromosome 11q22-23, this may be a mechanism for H2AX haploinsufficiency if this gene is involved in lymphomagenesis or disease progression. Of particular interest is MCL, characterized by the t(11;14) and deletions or inactivating mutations of ATM on 11q22. ATM is not inactivated in all MCLs, which have 11q deletions; thus, it could be the loss of one functional copy of H2AX, which has more extensive implications for the tumor. Another alternative is aberrant epigenetic modification or mutations in regulatory regions of the gene, which may contribute to the downregulation of H2AX.
